Aug 4 (Reuters) - LAVA Therapeutics NV ( LVTX ):

* XOMA ROYALTY ENTERS INTO AGREEMENT TO ACQUIRE LAVA

THERAPEUTICS

FOR BETWEEN $1.16 AND $1.24 PER SHARE IN CASH, PLUS A CONTINGENT

VALUE RIGHT

* XOMA ROYALTY CORP ( XOMA ) - ACQUISITION INCLUDES CVR FOR 75% OF

NET

PROCEEDS

* XOMA ROYALTY CORP ( XOMA ) - TO COMMENCE TENDER OFFER TO ACQUIRE

LAVA BY

AUGUST 15, 2025

* XOMA ROYALTY CORP ( XOMA ) - LAVA TO DISCONTINUE PHASE 1 TRIAL OF

LAVA-1266

* XOMA ROYALTY CORP ( XOMA ): LAVA TO UNDERGO CORPORATE

REORGANIZATION

DESIGNED TO RESULT IN XOMA ROYALTY ACQUIRING 100% OF SHARES IN

LAVA'S SUCCESSOR

* XOMA ROYALTY CORP ( XOMA ): LAVA TO INITIATE WIND-DOWN OF LAVA-1266

PROGRAM

Source text:

Further company coverage: